Pharvaris (PHVS)
Develops oral deucrictibant formulations to treat and prevent hereditary angioedema attacks.
Something off on this page? Send us feedback.
Develops immediate-release and extended-release formulations of deucrictibant, an oral bradykinin B2-receptor antagonist, for on-demand treatment and prevention of hereditary angioedema attacks. The program's path is shaped by FDA review and clinical development.
Develops deucrictibant, an oral bradykinin B2-receptor antagonist for bradykinin-mediated angioedema. An immediate-release formulation is intended for on-demand HAE attack treatment, while an extended-release formulation is being developed for prophylaxis.
Operates as a rare-disease biopharmaceutical company concentrated on two formulations of the same molecule. The company is headquartered in Leiden, Netherlands, and its ordinary shares trade on Nasdaq.
Development has been shaped by an FDA clinical hold that was lifted in stages after a toxicology study. The immediate-release formulation now has an accepted U.S. NDA for HAE attacks, while the extended-release program remains in pivotal development.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 14, 2026 | Cantor Fitzgerald | Reiterate | Rating: —Target: — | Target: $65 |
| Sep 10, 2026 | Guggenheim | Reiterate | Rating: —Target: $40 | Target: $44 |
| Sep 9, 2026 | Wedbush | Reiterate | Rating: —Target: $27 | Target: $50 |
| Sep 9, 2026 | Leerink Partners | Reiterate | Rating: —Target: $38 | Target: $65 |
| Sep 9, 2026 | RBC Capital | Reiterate | Rating: —Target: $52 | Target: $62 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $364.4M · Total debt $771.4K · Total assets $376.3M · Shareholders' equity $344.4M
- Revenue
- $0
- Operating income
- −$58.2M
- Net income
- −$54.8M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions | ≈ 92.22% | 64.44M ADS | |
|---|---|---|---|
| 130 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Other | ≈ 7.78% | 5.44M ADS | |
| remainder | |||
69.88M ADS as of Sep 15, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2023 annual report; nothing newer is on file here.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 9.40% | 6.57M ADS | as of Jun 30, 2026 |
General Atlantic, L.P.Institution | 9.37% | 6.55M ADS | as of Jun 30, 2026 |
Foresite Capital Management Iv, LLCInstitution | 6.84% | 4.78M ADS | as of Jun 30, 2026 |
Venbio Partners LLCInstitution | 6.64% | 4.64M ADS | as of Jun 30, 2026 |
Viking Global Investors LPInstitution | 5.23% | 3.65M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | Johannes Gerardus Christiaan Petrus Schikan | director | −200,000 | $35.00 |
| Sep 17, 2026 | Peng Lu | officer: President | −100,000 | $35.00 |
| Sep 17, 2026 | Robert Glassman | director | −14,493 | $38.56 |
| Sep 17, 2026 | Elisabeth Bjork | director | −52,500 | $37.89 |
| Sep 17, 2026 | Anne Lesage | officer: Chief Early Development | −20,000 | $38.27 |
- Takeda (ADR)
HAE attack treatment and prophylaxis across injectable options
- BioCryst Pharmaceuticals
Once-daily oral prophylaxis for HAE attacks
- Ionis Pharmaceuticals
RNA-targeted injectable prophylaxis for HAE attacks
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pharvaris | $35.43 | −1.65% | $2.52B | — | — | — | — |
| Takeda (ADR) | $19.01 | +0.61% | $60.11B | 52.5 | 60.1 | 2.0 | +4.2% |
| BioCryst Pharmaceuticals | $8.76 | 0.00% | $2.23B | — | 16.7 | 2.4 | +33.6% |
| Ionis Pharmaceuticals | $45.91 | +2.25% | $7.46B | — | — | 8.5 | −40.7% |
| Median | 52.5 | 38.4 | 2.4 | +4.2% |